Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Coen R. N. Rasch has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interpretable Survival Analysis with MultiFIX: Multimodal Feature Engineering for Risk Stratification

    by Mafalda Malafaia, Peter A. N. Bosman, Coen R. N. Rasch, Tanja Alderliesten

  • Open Access

    Towards FLASH Radiotherapy in Lung Cancer: A Review on Preclinical Evidence and Technical Feasibility

    by Simone N. Visser, Steven J. M. Habraken, Anggraeini Puspitasari-Kokko, Anne H. Zur Horst, Coen R. N. Rasch, Krista C. J. van Doorn-Wink

    Background/Objectives: Alongside surgery and systemic treatments, radiotherapy plays a crucial role in the treatment of lung cancer but can affect healthy tissue and cause serious side effects. Compared to photon therapy, proton therapy can lower toxicity because protons deposit most of their energy within the tumor (the Bragg peak), sparing healthy tissue. FLASH radiotherapy (FLASH-RT), which is characterized by using ultra-high dose rates (UHDR), may further enhance healthy tissue sparing. Preclinical studies using electrons, protons, or photons have shown that FLASH-RT may reduce toxicity, while tumor response is maintained, known as the FLASH-effect. FLASH-RT with protons (FLASH-PT) is a promising treatment for lung cancer, integrating the biological advantages of FLASH with the physical advantages of proton beams. Methods: A literature search was performed on preclinical evidence of the FLASH-effect on lung-related endpoints, the proposed mechanisms, and treatment planning and delivery strategies for FLASH-PT in lung cancer. Results: Preclinical studies have shown reduced pulmonary fibrosis, inflammation, vascular damage, and oxidative stress with FLASH-RT. Current evidence suggests that the FLASH-effect likely arises from multiple radiochemical and biological processes, can vary between tissues, and depends on dose, beam and/or delivery characteristics. Despite growing evidence, the exact dose delivery conditions and technological factors required to obtain a FLASH-effect remain unclear. Treatment planning studies achieved clinically acceptable thoracic FLASH-PT plans for lung cancer, with similar or improved organ-at-risk sparing compared with conventional radiotherapy, while meeting (fraction) dose and dose rate criteria for the FLASH-effect. However, clinically feasible technologies for conformal dose delivery under UHDR conditions with respiratory motion mitigation are still under development. Conclusions: FLASH-PT holds the potential to reduce radiation-induced pulmonary side effects and expand the therapeutic window of radiotherapy. Still, key (pre)clinical and technological challenges must be addressed before clinical implementation for patients with lung cancer.

  • Open Access

    Shared decision-making about uveal melanoma treatment in the Netherlands: non-neutral framing of medical information

    by Aryana Shirzada, Lisa Vlug, Marina Marinkovic, Gregorius P.M. Luyten, Jaco C. Bleeker, T.H. K Vu, Coen R.N. Rasch, Nanda Horeweg, Arwen Pieterse

    Background: A subset of uveal melanomas can be treated using either enucleation or proton beam therapy (PBT), which offer similar oncological outcomes. The most appropriate treatment depends on a patient's preference. To allow patients to genuinely determine their preference, it is recommended to describe options as neutrally as possible. This study assesses to what extent ocular oncologists use and perceive non-neutral framing behaviour, and if it is related to patient satisfaction with decision-making. Methods: Consultations of ocular oncologists with patients newly-diagnosed with uveal melanoma were audio recorded, transcribed verbatim, and coded for ocular oncologists' explicit and implicit non-neutral framing behaviours. Explicit non-neutral framing was defined as: explicitly mentioning a preferred option at least once, without relating it to the patient. Implicit non-neutral framing was defined as: describing an option (un)favourably, without providing a medically substantive clarification alongside. Results: 110 patients provided consent for the audio recordings. Non-neutral framing was found in 84% (n=92/110) of consultations. We found explicit behaviour in 38% (42/110) and implicit behaviour in 76% (84/110, median=1, range, 0-4) of consultations. The most frequent implicit framing was presenting options by positively or negatively emphasizing one option. Non-neutral framing behaviours were not significantly related to patient satisfaction with decision-making. Conclusion: This study shows that in most consultations some non-neutral framing was present, which did not impact patients' satisfaction with decision-making. Nonetheless, ocular oncologists should be aware that how they describe options may influence preferences in ways that do not align with the patient's values.

  • Top Cited Papers
    Open Access

    Stereotactic arrhythmia radioablation for refractory ventricular tachycardia: the STOPSTORM.eu study

    by L H G van der Pol, Bartłomiej Tomasik, Wiert F Hoeksema, Stefano Mandija, Marcin Miszczyk, Melanie Grehn, Jasna But Hadzic, David Calvo, Chiara Crico, Jakub Cvek, et al.

    Background and Aims: Stereotactic arrhythmia radioablation (STAR) is increasingly used for refractory ventricular tachycardia (VT), yet prospective multicentre outcome data remain limited. Here, the planned interim analysis of the prospective Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) registry is reported. Methods: STOPSTORM is a European prospective, international, multicentre registry of patients treated with STAR. The primary efficacy endpoint was the change in sustained VT episode burden comparing the 6 months before versus the 6 months after STAR. The primary safety endpoint was the occurrence of serious adverse events (SAEs) adjudicated as possibly or probably treatment-related. Overall survival was assessed using time-to-event methods. Results: Across 28 centres, 193 patients were included (mean age 68±9 years; 88% male; 53% non-ischaemic cardiomyopathy). Median follow-up was 19 months. Among 107 evaluable patients with ≥6-month follow-up, the median VT episode burden was reduced by 80% after STAR. Among patients surviving ≥6 months, 72% were free from implantable cardioverter-defibrillator (ICD) shock. In the full cohort, 12 SAEs were adjudicated as possibly or probably treatment-related, including pericardial effusion, coronary events, and early post-treatment ventricular arrhythmia. Overall survival probability was 77% at 12 months. Conclusions: In the largest prospective multicentre cohort reported to date, STAR was associated with a substantial reduction in VT burden and ICD shocks, with a low frequency of possibly or probably treatment-related SAEs.


  • Open Access

    Estimation of accumulated dose to organs at risk in head and neck cancer patients treated with scheduled replanning and dose painting in the ARTFORCE trial

    by Anna Liza M.P. de Leeuw, Simon R. van Kranen, Jordi Giralt, Yungan Tao, Sergi Benavente, Thanh-Vân F. Nguyen, Frank J.P. Hoebers, Ann Hoeben, Chris H.J. Terhaard, Lip Wai Lee, et al.

  • Open Access

    Automated and Interpretable Survival Analysis from Multimodal Data

    by Mafalda Malafaia, Peter A. N. Bosman, Coen Rasch, Tanja Alderliesten

    Accurate and interpretable survival analysis remains a core challenge in oncology. With growing multimodal data and the clinical need for transparent models to support validation and trust, this challenge increases in complexity. We propose an interpretable multimodal AI framework to automate survival analysis by integrating clinical variables and computed tomography imaging. Our MultiFIX-based framework uses deep learning to infer survival-relevant features that are further explained: imaging features are interpreted via Grad-CAM, while clinical variables are modeled as symbolic expressions through genetic programming. Risk estimation employs a transparent Cox regression, enabling stratification into groups with distinct survival outcomes. Using the open-source RADCURE dataset for head and neck cancer, MultiFIX achieves a C-index of 0.838 (prediction) and 0.826 (stratification), outperforming the clinical and academic baseline approaches and aligning with known prognostic markers. These results highlight the promise of interpretable multimodal AI for precision oncology with MultiFIX.

  • Open Access

    Excellent interobserver agreement and steep learning curve for target volume delineation for stereotactic arrhythmia radioablation using a commercial software

    by Robert Rademaker, Simon Cirkel, Sharif Omara, Frank J W M Dankers, Marek Sramko, J Solana Munoz, Yesim S Kaya, Rachel M A Ter Bekke, Luis Schiappacasse, Cheryl Teres, et al.

    Aims: Stereotactic arrhythmia radioablation (STAR) has emerged as bail-out treatment for ventricular tachycardia (VT). Accurate, reproducible, and easy-to-use data transfer from electroanatomical mapping (EAM) systems to radiotherapy planning CT is desirable. We aim to evaluate interobserver variability, ease of use, and learning curve for EAM based target volume (CardTV-EPinv) creation and transfer using available software packages. Methods and results: In patients considered for STAR, CardTV-EPinv were created using ADAS and Slicer3D for workflow comparison. Four CardTV-EPinv (clinically targeted volume and three mock targets) were created by an experienced operator and a 2nd-year medical student, based on endocardial EAM tags indicating VT substrate location. CardTV-EPinv sizes, Hausdorff distances (HDs), and workflow duration were measured to assess interobserver variability and learning curve. Agreement between CardTV-EPinv was high using ADAS and Slicer3D workflows (HD 3.64 mm [2.7–4.5]). ADAS workflow was faster and more robust (ADAS 26 min [24–29] vs. Slicer3D 65 min [61–70], P < 0.001; system crashes: ADAS 0 vs. Slicer3D 7). In 20 patients (80% non-ischaemic cardiomyopathy, LVEF 35 ± 14%), 80 CardTV-EPinv were created using ADAS. CardTV-EPinv size was similar for both observers (11.8 mL [10.1–13.7] vs. 10.7 mL [9.6–11.8], P = 0.17), with high interobserver agreement (HD 1.68 mm [1.45–1.96]; 95th percentile HD < 4.8 mm [3.5–5.7]). Linear regression showed a steep learning curve for the student (P = 0.01). Conclusion: CardTV-EPinv creation showed excellent interobserver agreement and was faster and more robust using ADAS than 3D slicer. The steep learning curve appears clinically relevant given the limited use of STAR even in high-volume VT ablation centres.


  • Open Access

    Choroidal melanoma patient views on the importance of treatment characteristics and outcomes, and physicians' information provision in the Netherlands

    by Aryana Shirzada, Arwen H. Pieterse, Lisa Vlug, Gré P. M. Luyten, T. H. Khanh Vu, Jaco C. Bleeker, Pauline A. Bakker, Marina Marinkovic, Coen R. N. Rasch, Nanda Horeweg, et al.

    Purpose: To identify the treatment characteristics and outcomes that Dutch patients with large or juxtapapillary choroidal melanoma consider important when choosing between enucleation and proton beam therapy (PBT). We further determined to what extent these treatment characteristics and outcomes are discussed with newly diagnosed choroidal melanoma patients.Methods: Through a literature search, stakeholder interviews and feedback from patients, we identified 15 treatment characteristics and outcomes that patients might consider important for deciding between enucleation and PBT. Using a ranking survey, we selected the seven most important characteristics. Next, we conducted a Swing Weighting (SW) survey among treated and newly diagnosed large or juxtapapillary choroidal melanoma patients to determine the relative weight patients assign to these characteristics for treatment decision‐making. Furthermore, we assessed which characteristics and outcomes are discussed in current practice with newly diagnosed choroidal melanoma patients eligible for both enucleation and PBT using audio recordings of consultations.Results: One hundred sixty‐five participants completed the SW survey. The patients found the risk of tumour recurrence and eye loss most important. These were mentioned in 47% and 42% of the 110 audio‐recorded consultations, respectively. The two most‐often mentioned characteristics were treatment course (96%) and decrease in visual acuity (85%).Conclusion: Tumour local control and eye preservation matter the most to newly diagnosed choroidal melanoma patients when facing a treatment decision. However, ocular oncologists do not routinely provide this information to patients. The results can be used to align counselling of newly diagnosed patients with choroidal melanoma with what matters most to patients.


  • Open Access

    Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity

    by Anna C. Nuijens, Arlene L. Oei, Nicolaas A. P. Franken, Coen R. N. Rasch, Lukas J. A. Stalpers

    Normal tissue reactions vary significantly among patients receiving the same radiation treatment regimen, reflecting the multifactorial etiology of late radiation toxicity. Predicting late radiation toxicity is crucial, as it aids in the initial decision-making process regarding the treatment modalities. For patients undergoing radiotherapy, anticipating late toxicity allows for planning adjustments to optimize individualized care. Various dosimetric parameters have been shown to influence the incidence of late toxicity, and the literature available on this topic is extensive. This narrative review examines patient-related determinants of late toxicity following external beam radiotherapy for pelvic tumors, with a focus on prostate and cervical cancer patients. In Part I, we address various methods for quantifying radiation toxicity, providing context for interpreting toxicity data. Part II examines the current insights into the clinical risk factors for late toxicity. While certain factors—such as previous abdominal surgery, smoking behavior, and severe acute toxicity—have consistently been reported, most of the others show inconsistent associations. In Part III, we explore the influence of genetic factors and discuss promising predictive assays. Single-nucleotide polymorphisms (SNPs) likely elevate the risk in specific combinations. Advances in artificial intelligence now allow for the identification of SNP patterns from large datasets, supporting the development of polygenic risk scores. These innovations hold promise for improving personalized treatment strategies and reducing the burden of late toxicity in cancer survivors.